Chronic Granulomatous Disease Clinical Trial
Official title:
A Retrospective Analysis of Efficacy and Safety of Interleukin-1 Receptor Inhibitor for the Treatment of Granulomatous Complications in Patients With Chronic Granulomatous Disease
"Kineret" (INN: Anakinra) neutralizes the biological activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by the concurrent inhibition of binding to interleukin-1 receptor I (IL-1RI). Interleukin-1 (IL-1) is the main pro-inflammatory cytokine that mediates many cellular responses. Anakinra inhibits the reactions caused by IL-1 in vitro, including the induction of nitric oxide and prostaglandin E2 and / or the formation of collagenase by synovial cells, fibroblasts and chondrocytes. According to published data, patients with the chronic granulomatous disease have an increased secretion of interleukin-1, which contributes to the development of granulomatous inflammation. Blocking interleukin-1 reduces the activity of the main pro-inflammatory complex - the inflammasomes, and also restores the autophagy process impaired in patients with chronic granulomatous disease. In this way, inhibition of the IL-1 receptor prevents the activation of innate immunity cells and prevents the maintenance of pathological pro-inflammatory signaling in conditions of IL-1 overproduction. The efficacy and safety of therapy with the above drug is based on the results of international studies on the using of anakinra in patients with chronic granulomatous disease.
The research will include a group of patients with a molecular-genetic confirmed diagnosis of
chronic granulomatous disease, which has granulomatous complications on the basis of an
initial comprehensive survey.
This examination will include clinical data; laboratory tests - clinical and biochemical
analysis of blood (with an assessment of inflammatory activity); molecular-genetic methods
for detecting mutations in the genes CYBB, CYBA, NCF2, NCF1 or NCF4; methods for studying the
functional activity of neutrophils (chemiluminescence of neutrophils, test with rhodamine);
methods for assessing pro-inflammatory interleukins; microbiological testing of
bronchoalveolar lavage; histological studу of lung biopsies; as well as the results of
visualization techniques (ultrasound investigation of the abdominal organs, CT scan of the
chest and abdominal organs). Negative galactomannan and lack of microorganism growth in
bronchoalveolar lavage and/or lack of response to complex antibacterial and antifungal
therapy for two to three weeks confirm the presence of granulomatous complications in
patients. The next step is therapy with an inhibitor of IL-1 receptor (Anakinra). Evaluation
of the efficacy and safety therapy is based on the results of control examinations after 3-6
months from the start of treatment and includes an assessment of the level of C-reactive
protein and pro-inflammatory cytokines, as well as the results of CT scan of the chest and
abdominal organs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03278912 -
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
|
||
| Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Terminated |
NCT03080480 -
Pioglitazone Therapy for Chronic Granulomatous Disease
|
Phase 1/Phase 2 | |
| Terminated |
NCT00394316 -
Gene Therapy for Chronic Granulomatous Disease
|
Early Phase 1 | |
| Recruiting |
NCT03910452 -
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
|
Early Phase 1 | |
| Terminated |
NCT02282904 -
Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
|
Phase 1/Phase 2 | |
| Terminated |
NCT02926963 -
Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease.
|
N/A | |
| Completed |
NCT00006417 -
Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease
|
Phase 2 | |
| Completed |
NCT00368446 -
Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
|
||
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Recruiting |
NCT06162936 -
Neutrophil Oxidative Burst in Early and Late Onset Pediatric Inflammatory Bowel Disease
|
||
| Terminated |
NCT05915897 -
Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)
|
||
| Terminated |
NCT00325078 -
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT00001317 -
A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood
|
Phase 4 | |
| Completed |
NCT03548818 -
Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
|
||
| Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
| Completed |
NCT00578643 -
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
|
Phase 2 | |
| Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
| Enrolling by invitation |
NCT06253507 -
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
|
Phase 1/Phase 2 |